Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
Ernexa Therapeutics (NASDAQ: ERNA) has announced new data presentation at the AACR Annual Meeting 2025 in Chicago, showcasing their lead cell therapy product ERNA-101. The study, led by Dr. Michael Andreeff from MD Anderson Cancer Center, explores a novel treatment for ovarian cancer using engineered cells that deliver therapy directly to tumors.
The technology works by secreting immune-stimulating cytokines to reshape the tumor microenvironment and enhance anti-tumor immune responses. The presentation will take place on Monday, April 28, 2025, from 2:00-5:00 pm CDT in the Immunology session, focusing on local treatments and novel delivery systems to manipulate tumor immunity.
Ernexa Therapeutics (NASDAQ: ERNA) ha annunciato la presentazione di nuovi dati al AACR Annual Meeting 2025 di Chicago, mostrando il loro prodotto principale di terapia cellulare ERNA-101. Lo studio, guidato dal Dr. Michael Andreeff del MD Anderson Cancer Center, esplora un trattamento innovativo per il cancro ovarico utilizzando cellule ingegnerizzate che rilasciano la terapia direttamente nei tumori.
La tecnologia funziona secernendo citochine immunostimolanti per rimodellare il microambiente tumorale e potenziare le risposte immunitarie antitumorali. La presentazione si terrà il lunedì 28 aprile 2025, dalle 14:00 alle 17:00 CDT nella sessione di Immunologia, con focus sui trattamenti locali e nuovi sistemi di somministrazione per manipolare l’immunità tumorale.
Ernexa Therapeutics (NASDAQ: ERNA) ha anunciado la presentación de nuevos datos en la AACR Annual Meeting 2025 en Chicago, mostrando su producto principal de terapia celular ERNA-101. El estudio, liderado por el Dr. Michael Andreeff del MD Anderson Cancer Center, explora un tratamiento novedoso para el cáncer de ovario usando células diseñadas para administrar la terapia directamente a los tumores.
La tecnología funciona secretando citocinas que estimulan el sistema inmunológico para remodelar el microambiente tumoral y mejorar las respuestas inmunes antitumorales. La presentación tendrá lugar el lunes 28 de abril de 2025, de 2:00 a 5:00 pm CDT en la sesión de Inmunología, enfocada en tratamientos locales y nuevos sistemas de administración para manipular la inmunidad tumoral.
Ernexa Therapeutics (NASDAQ: ERNA)가 시카고에서 열리는 AACR Annual Meeting 2025에서 주요 세포 치료제 ERNA-101에 대한 새로운 데이터 발표를 했습니다. MD Anderson Cancer Center의 Dr. Michael Andreeff가 이끄는 연구는 종양에 직접 치료제를 전달하는 조작된 세포를 이용한 난소암의 새로운 치료법을 탐구합니다.
이 기술은 면역 자극성 사이토카인을 분비하여 종양 미세환경을 재구성하고 항종양 면역 반응을 강화합니다. 발표는 2025년 4월 28일 월요일 오후 2시부터 5시까지 CDT 시간으로 면역학 세션에서 진행되며, 국소 치료와 종양 면역 조작을 위한 새로운 전달 시스템에 중점을 둡니다.
Ernexa Therapeutics (NASDAQ : ERNA) a annoncé la présentation de nouvelles données lors du AACR Annual Meeting 2025 à Chicago, mettant en avant leur produit principal de thérapie cellulaire ERNA-101. L’étude, dirigée par le Dr Michael Andreeff du MD Anderson Cancer Center, explore un traitement innovant du cancer de l’ovaire utilisant des cellules modifiées qui délivrent la thérapie directement aux tumeurs.
La technologie fonctionne en sécrétant des cytokines immunostimulantes pour remodeler le microenvironnement tumoral et renforcer les réponses immunitaires anti-tumorales. La présentation aura lieu le lundi 28 avril 2025, de 14h00 à 17h00 CDT lors de la session d’Immunologie, axée sur les traitements locaux et les nouveaux systèmes d’administration pour moduler l’immunité tumorale.
Ernexa Therapeutics (NASDAQ: ERNA) hat neue Datenpräsentationen auf dem AACR Annual Meeting 2025 in Chicago angekündigt und stellt dabei ihr führendes Zelltherapie-Produkt ERNA-101 vor. Die Studie, geleitet von Dr. Michael Andreeff vom MD Anderson Cancer Center, untersucht eine neuartige Behandlung von Eierstockkrebs mit gentechnisch veränderten Zellen, die die Therapie direkt an die Tumore liefern.
Die Technologie funktioniert durch die Sekretion immunstimulierender Zytokine, um das Tumormikroumfeld umzuwandeln und die antitumoralen Immunantworten zu verstärken. Die Präsentation findet am Montag, den 28. April 2025, von 14:00 bis 17:00 Uhr CDT in der Immunologie-Sitzung statt, die sich auf lokale Behandlungen und neuartige Liefersysteme zur Beeinflussung der Tumorimmunität konzentriert.
- Novel cell therapy technology targeting difficult-to-treat ovarian cancer
- Collaboration with prestigious MD Anderson Cancer Center
- None.
Conference attendees will get first look at new data that supports the potential of ERNA-101 to boost anti-tumor immunity in ovarian cancer
CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.
The study explored the technology behind Ernexa’s lead cell therapy product, ERNA-101, which uses specially engineered cells to deliver treatment directly to ovarian tumors. By secreting immune-stimulating cytokines, this cell therapy treatment aims to reshape the tumor microenvironment and enhance anti-tumor immune responses, fighting off the cancer. The study was led by Michael Andreeff, M.D., Ph.D., from The University of Texas MD Anderson Cancer Center.
“We believe ERNA-101 represents a powerful new way to engage the immune system against difficult-to-treat cancers like ovarian cancer,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “This study reinforces the promise of our treatments and their potential to reshape the future of cell therapy. We aim to offer hope for patients with advanced ovarian cancer, who often face limited treatment options and poor long-term outcomes.”
Details of the poster presentation session include:
Session Category: Immunology
Session Title: Local Treatments, Novel Tools, and Delivery Systems to Manipulate Tumor Immunity
Date and Time: Monday, April 28, 2025 at 2:00–5:00 pm CDT
Location: Poster Section 37
Poster Board Number: 12
Published Abstract Number: 3473
Conference attendees can learn the results of the study at the presentation. They can also meet with Ernexa’s Chief Scientific Officer, Robert Pierce, M.D., and the study’s authors.
About ErnexaTherapeutics
Ernexa Therapeutics (Nasdaq: ERNA) is developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune disease. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
Ernexa is developing two highly innovative cell therapy products, both currently in preclinical stages. ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media & Investor Relations Contact
FAQ
What is ERNA-101 and how does it treat ovarian cancer?
When and where will Ernexa (ERNA) present their new cancer treatment data?
What type of cancer does ERNA-101 target?
Who led the research study for Ernexa's ERNA-101 treatment?
